ACCELERATE Peanut Study | IgGenix Australia Pty Ltd

Have You or Your Teen Been Diagnosed with Peanut Allergy?

You may be eligible
for a new research study.

IgGenix ACCELERATE Peanut Study

If you or your teen has been diagnosed with peanut allergy, you may be eligible to take part in a new study exploring whether an investigational medicine called IGNX001 can help treat peanut allergy in teens and adults.

Overview

The phase 1, randomised, double-blind study will evaluate the safety and tolerability of an injectable, allergen-specific antibodies that targets peanut protein.

The study will help understand if IGNX001 can be used to help ease allergic reactions that might happen after accidental peanut exposure. It will monitor the safety of IGNX001, track how participants respond to it, and explore whether participants improve their tolerance to peanut protein exposure after receiving IGNX001.

The study is recruiting participants at Fiona Stanley Hospital (Western Australia), St Vincent’s Hospital (New South Wales), The Royal Melbourne Hospital and Monash Health (Victoria).

What’s involved in the study

The study runs for up to six months, and involves:

Regular visits to your study centre
Receiving up to four injections
Undertaking a series of tests and assessments to monitor your health during the study, including your medical history, prior and current medications, physical exams, blood and urine samples, electrocardiograms (ECG), skin prick tests and peanut oral food challenges.

Who can take part?

To pre-qualify for this study, you or your teen must:

Be 15 to 55 years old
Have a history of peanut allergy, including having experienced a serious allergic reaction to peanut in the past 15 years
Be willing to avoid peanuts and other allergy inducing foods during the study.

You or your teen cannot take part if you have:

A history of severe or life-threatening anaphylaxis requiring admission to the intensive care unit within the last year
A history of severe or uncontrolled asthma within the past six months
Any clinically significant liver, kidney, cardiac or mast cell disease or uncontrolled chronic disease
Received food allergen immunotherapy treatment or participated in a similar study in the past 12 months